Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 registratinal study of Lixivaptan

Next Previous
Trial Profile

Phase 3 registratinal study of Lixivaptan

Planning
Phase of Trial: Phase III

Latest Information Update: 14 May 2018

At a glance

  • Drugs Lixivaptan (Primary)
  • Indications Polycystic kidney disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Palladio Biosciences

    • Most Recent Events

    • 14 May 2018 New trial record
    • 08 May 2018 According to Palladio Biosciences media release, study will initiate in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top